Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 4,491 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Thorax Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Rociletinib; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 11
States / cities: Scottsdale, Arizona • Fountain Valley, California • Monterey, California + 8 more

Conditions: Non Small Cell Lung Cancer, Breast Cancer
Interventions: Abemaciclib, Pembrolizumab, Anastrozole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: AMG 479, Everolimus, Panitumumab; Drug
Lead sponsor: Jeffrey Clarke; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Non-Small-Cell-Lung Cancer (NSCLC)
Interventions: 18F-FMISO, PET/CT; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumors
Interventions: Bemarituzumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Duarte, California • Orange, California • Aurora, Colorado + 7 more

Conditions: TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions: Sterotactic Body Radiotherapy/SBRT, Standard of care; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Vorolanib, Atezolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7, Stage IIA Lung Carcinoma, Stage IIIA Lung Carcinoma
Interventions: Vitamin A Compound, Therapeutic Conventional Surgery; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy; Drug · Radiation
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Gilbert, Arizona • Tucson, Arizona • Seattle, Washington

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Interventions: Azacitidine, Entinostat, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Lexington, Kentucky • Albuquerque, New Mexico • Dallas, Texas

Conditions: Lung Cancer
Interventions: erlotinib hydrochloride, fulvestrant; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer
Interventions: Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification; Behavioral
Lead sponsor: Complement Theory Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dover, Delaware

Conditions: Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Osimertinib, Carboplatin, Pemetrexed; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Sacramento, California • San Francisco, California • Tampa, Florida + 13 more

Conditions: Small Cell Lung Cancer
Interventions: Rucaparib and Nivolumab; Combination Product
Lead sponsor: Zhonglin Hao; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Tumors
Interventions: Clostridium novyi-NT spores; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HER2-positive Advanced Solid Tumor
Interventions: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole; Biological · Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Cerritos, California • Los Angeles, California • San Diego, California + 29 more

Conditions: Lung Cancer
Interventions: CT Scans, Implanted markers, Radiation Treatment (RT); Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions: SGN-CD47M; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more

Conditions: Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
Interventions: LMB-100, pembrolizumab, Mesothelin Expression, TrueSight Oncology 500; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasm Metastasis, Brain Neoplasms
Interventions: Motexafin gadolinium; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more

Conditions: Lung Cancer
Interventions: carboplatin, vinorelbine ditartrate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: Questionnaires, Meditation and Discussion Sessions, Cancer-Related Discussion Program; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Rociletinib (CO-1686) USA Expanded Access Program

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

A Safety Study of SGN-CD47M in Patients With Solid Tumors

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer